Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16987574 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL16987573 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL16787484 | 0.84 | MEN1 (0.59) | MEN1KMT2AMAPTALDH1A1GSK3B | |
| SCHEMBL16762221 | 0.77 | XDH (0.53) | MEN1KMT2ARAB9AMAOAGSK3B | |
| SCHEMBL16762223 | 0.77 | XDH (0.53) | MEN1KMT2ARAB9AMAOAGSK3B | |
| SCHEMBL14622042 | 0.76 | PTGS1 (0.43) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL19287965 | 0.75 | SMN1; SMN2 (0.38) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL16998374 | 0.74 | MAOA (0.37) | MEN1KMT2AMAPTKDM4EALDH1A1 | |
| SCHEMBL16762252 | 0.72 | PIM1 (0.61) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL16762254 | 0.72 | PIM1 (0.61) | MEN1KMT2AMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | MEN1 31/4885KMT2A 277/4885MAPT 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.